Her2 Targeting
Her2 Targeting - Related Videos
11:52
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
0 Views •
Cited by 1 •
2013
This article details the procedures for optical imaging analysis of the tumor-targeted nanoparticle, HerDox. In particular, detailed use of the multimode imaging device for detecting tumor targeting and assessing tumor penetration is described here.
10:21
Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
0 Views •
Cited by 3 •
2017
Fluorescence in-situ hybridization (FISH) is often required in combination with histopathology and molecular diagnostics for selection of therapy in personalized medicine. A novel non-cross-linking, formalin-free tissue fixative that allows high quality morphologic, molecular and FISH analyses from the same specimen by addition of a post-fixation step before FISH is presented.
11:34
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
0 Views •
Cited by 19 •
2017
Heterogeneous distribution of HER2-positive cells can be observed in a subset of breast cancers and generates clinical dilemmas. Here, we introduce a reliable and cost-effective protocol to define, quantify, and compare HER2 intra-tumor genetic heterogeneity in a large series of heterogeneously processed breast cancers.
08:40
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
0 Views •
Cited by 1 •
2012
The Target ID Library is a plasmid-based, genome-wide collection of cloned cDNA used to identify miRNA targets. Here we demonstrate its use and application.
08:56
Recombineering and Gene Targeting
0 Views •
2023
One of the most widely used tools in modern biology is molecular cloning with restriction enzymes, which create compatible ends between DNA fragments that allow them to be joined together. However, this technique has certain restrictions that limit its applicability for large or complex DNA construct generation. A newer technique that addresses some of these shortcomings is recombineering, which modifies DNA using homologous recombination (HR), the exchange between different DNA molecules based...
FAQs
HER2 targeting can act through two chemically distinct access points. Antibodies and other ligands recognize the receptor’s extracellular domain, whereas small-molecule inhibitors are designed to occupy its intracellular kinase site. This difference affects ligand architecture, molecular accessibility, and the biological outcome being studied, helping chemists select an approach for signaling control, treatment delivery, or inhibitor optimization.
In an antibody-drug conjugate, the linker chemically connects the HER2-binding antibody to a cytotoxic payload. Its design therefore links molecular recognition with transport of the treatment component into HER2-positive cells. Conjugation chemistry must preserve the antibody’s ability to recognize the receptor while incorporating the payload, making linker selection central to developing selective therapeutic constructs.
Ligand optimization determines how effectively a molecule recognizes HER2 and how suitable it is for a particular application. Chemists can refine the ligand while considering whether the construct should alter receptor signaling, deliver a payload, support imaging, or occupy the kinase site. These design choices connect molecular structure with selectivity and the intended biological outcome.
Biomarker information helps identify tumors in which HER2 is overexpressed and may therefore support selective treatment or analysis. This information connects receptor recognition with patient selection and assay development. In practice, molecular assays can help characterize HER2 status, while the resulting classification guides whether a HER2-directed therapeutic or imaging strategy is relevant.
A typical development workflow combines ligand design or optimization, selection of the desired receptor-binding or kinase-directed architecture, and testing through relevant assays. If treatment delivery is required, chemists add conjugation chemistry to connect a cytotoxic payload through a linker. These stages generate evidence about recognition, selectivity, and suitability for therapeutic or imaging applications.
Researchers may apply HER2 targeting when receptor overexpression provides a basis for distinguishing relevant cancer cells from other cells. The same recognition principle can support biomarker-based patient selection, molecular imaging, or delivery of a cytotoxic payload. Chemistry contributes by adapting ligands, linkers, and assay systems to the specific precision-treatment or detection objective.